Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 22584-22605

  Perri, Valentina ^a   Russo, Benedetta ^a   Crinò, Antonino ^a   Schiaffini, Riccardo ^a   Giorda, Ezio ^a   Cappa, Marco ^a   Rosado, Maria Manuela ^b   Fierabracci, Alessandra ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Immunology Consultant   (Italy)

Author keywords

Programmed cell death 1 programmed cell death ligand 1; T regulatory cells; Type 1 diabetes

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; HEMOGLOBIN A1C; INTERLEUKIN 10; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; VITILIGO; YOUNG ADULT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84942163682     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160922584     Document Type: Article

References (67)

1. Fierabracci, A. The potential of multimer technologies in type 1 diabetes prediction strategies. Diabetes Metab. Res. Rev. 2011, 27, 216–229
2. Fierabracci, A. Recent insights into the role and molecular mechanisms of the autoimmune regulator (AIRE) gene in autoimmunity. Autoimmun. Rev.2011, 10, 137–143
3. Putnam, A.L.; Vendrame, F.; Dotta, F.; Gottlieb, P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun.2005, 24, 55–62
4. Tan, T.; Xiang, Y.; Chang, C.; Zhou, Z. Alteration of regulatory T cells in type 1 diabetes mellitus: A comprehensive review. Clin. Rev. Allergy Immunol. 2014, 47, 234–243
5. Kukreja, A.; Cost, G.; Marker, J.; Zhang, C.; Sun, Z.; Lin-Su, K.; Ten, S.; Sanz, M.; Exley, M.; Wilson, B., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Investig. 2002, 109, 131–140
6. Lindley, S.; Dayan, C.M.; Bishop, A.; Roep, B.O.; Peakman, M.; Tree, T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54, 92–99
7. Łuczyński, W.; Wawrusiewicz-Kurylonek, N.; Stasiak-Barmuta, A.; Urban, R.; Iłendo, E.; Urban, M.; Hryszko, M.; Kretowski, A.; Górska, M. Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta Biochim. Pol. 2009, 56, 361–700
8. Lawson, J.M.; Tremble, J.; Dayan, C.; Beyan, H.; Leslie, R.D.G.; Peakman, M.; Tree, T.I. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 2008, 154, 353–359
9. Brusko, T.M.; Wasserfall, C.H.; Clare-Salzler, M.J.; Schatz, D.A.; Atkinson, M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54, 1407–1414
10. Moniuszko, M.; Glowinska-Olszewska, B.; Rusak, M.; Jeznach, M.; Grubczak, K.; Lipinska, D.; Milewski, R.; Milewska, A.J.; Dabrowska, M.; Jablonska, E., et al. Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127− T-cells in children with long-lasting type 1 diabetes. Clin. Dev. Immunol. 2013, 2013, 459210
11. Menart-Houtermans, B.; Rütter, R.; Nowotny, B.; Rosenbauer, J.; Koliaki, C.; Kahl, S.; Simon, M.C.; Szendroedi, J.; Schloot, N.C.; Roden, M., et al. Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: Results from the German Diabetes Study (GDS). Diabetes Care 2014, 37, 2326–2333
12. Brusko, T.; Wasserfall, C.; McGrail, K.; Schatz, R.; Viener, H.L.; Schatz, D.; Haller, M.; Rockell, J.; Gottlieb, P.; Clare-Salzler, M., et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007, 56, 604–612
13. Schneider, A.; Rieck, M.; Sanda, S.; Pihoker, C.; Greenbaum, C.; Buckner, J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181, 7350–7355
14. Monti, P.; Scirpoli, M.; Maffi, P.; Piemonti, L.; Secchi, A.; Bonifacio, E.; Roncarolo, M.G.; Battaglia, M. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57, 2341–2347
15. Glisic-Milosavljevic, S.; Waukau, J.; Jailwala, P.; Jana, S.; Khoo, H.-J.; Albertz, H.; Woodliff, J.; Koppen, M.; Alemzadeh, R.; Hagopian, W., et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS ONE 2007, 2, e146
16. Hughson, A.; Bromberg, I.; Johnson, B.; Quataert, S.; Jospe, N.; Fowell, D.J. Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes. Diabetes 2011, 60, 2125–2133
17. Glisic, S.; Ehlenbach, S.; Jailwala, P.; Waukau, J.; Jana, S.; Ghosh, S. Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Cell Tissue Res. 2010, 339, 585–595
18. McClymont, S.A.; Putnam, A.L.; Lee, M.R.; Esensten, J.H.; Liu, W.; Hulme, M.A.; Woodliff, J.; Koppen, M.; Alemzadeh, R.; Hagopian, W., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 2011,186, 3918–3926
19. Du, W.; Shen, Y.-W.; Lee, W.-H.; Wang, D.; Paz, S.; Kandeel, F.; Liu C.P. Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals. PLoS ONE 2013, 8, e56209
20. Marwaha, A.K.; Crome, S.Q.; Panagiotopoulos, C.; Berg, K.B.; Qin, H.; Ouyang, Q.; Xu, L.; Priatel, J.J.; Levings, M.K.; Tan, R. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 2010, 185, 3814–3818
21. Alonso, N.; Martínez-Arconada, M.J.; Granada, M.L.; Soldevila, B.; Cantón, A.; Mate, J.L.; Sanmartí, A.; Martínez-Cáceres, E.M. Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis. Endocrine 2009, 35, 420–428
22. Haseda, F.; Imagawa, A.; Murase-Mishiba, Y.; Terasaki, J.; Hanafusa, T. CD4+ CD45RA− FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin. Exp. Immunol. 2013, 173, 207–216
23. Badami, E.; Sorini, C.; Coccia, M.; Usuelli, V.; Molteni, L.; Bolla, A.M.; Scavini, M.; Mariani, A.; King, C.; Bosi, E., et al. Defective differentiation of regulatory FoxP3+ T cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes 2011, 60, 2120–2124
24. Ferraro, A.; Socci, C.; Stabilini, A.; Valle, A.; Monti, P.; Piemonti, L.; Nano, R.; Olek, S.; Maffi, P.; Scavini, M., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60, 2903–2913
25. Liu, W.; Putnam, A.L.; Zhou, X.-Y.; Szot, G.L.; Lee, M.R.; Zhu, S.; Gottlieb, P.A.; Kapranov, P.; Gingeras, T.R.; Fazekas de St Groth, B., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med.2006, 203, 1701–1711
26. Morikawa, H.; Sakaguchi, S. Genetic and epigenetic basis of Treg cell development and function: From a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol. Rev. 2014, 259, 192–205
27. Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T.; Miyara, M.; Fehervari, Z.; Nomura, T.; Sakaguchi, S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322, 271–275
28. Dwyer, K.M.; Deaglio, S.; Gao, W.; Friedman, D.; Strom, T.B.; Robson, S.C. CD39 and control of cellular immune responses. Purinergic Signal 2007, 3, 171–180
29. Huang, C.-T.; Workman, C.J.; Flies, D.; Pan, X.; Marson, A.L.; Zhou, G.; Hipkiss, E.L.; Ravi, S.; Kowalski, J.; Levitsky, H.I., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21, 503–513
30. Garín, M.I.; Chu, C.-C.; Golshayan, D.; Cernuda-Morollón, E.; Wait, R.; Lechler, R.I. Galectin-1: A key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007, 109, 2058–2065
31. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.-K.L.; Flavell, R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24, 99–146
32. Cao, X.; Cai, S.F.; Fehniger, T.A.; Song, J.; Collins, L.I.; Piwnica-Worms, D.R.; Ley, T.J. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27, 635–646
33. Shen, L.-S.; Wang, J.; Shen, D.-F.; Yuan, X.-L.; Dong, P.; Li, M.-X.; Xue, J.; Zhang, F.M.; Ge, H.L.; Xu, D. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin. Immunol. 2009, 131, 109–118
34. Gianchecchi, E.; Delfino, D.V.; Fierabracci, A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev.2013, 12, 1091–1100
35. Appleman, L.J.; van Puijenbroek, A.A.; Shu, K.M.; Nadler, L.M.; Boussiotis, V.A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 2002, 168, 2729–2736
36. Barthel, A.; Okino, S.T.; Liao, J.; Nakatani, K.; Li, J.; Whitlock, J.P.; Roth, R.A. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem.1999, 274, 20281–20286
37. Parry, R.V.; Chemnitz, J.M.; Frauwirth, K.A.; Lanfranco, A.R.; Braunstein, I.; Kobayakshi, S.V.; Linsley, P.S.; Thompson, C.B.; Riley, J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol.2005, 25, 9543–9553
38. Parry, R. V.; Reif, K.; Smith, G.; Sansom, D.M.; Hemmings, B.A.; Ward, S.G. Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur. J. Immunol. 1997, 27, 2495–2501
39. Frauwirth, K.A.; Riley, J.L.; Harris, M.H.; Parry, R.V.; Rathmell, J.C.; Plas, D.R.; Yamazaki, T.; Azuma, M.; Iwai, H.; Khoury, S.J. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002,16, 769–777
40. Ansari, M.J.; Salama, A.D.; Chitnis, T.; Smith, R.N.; Yagita, H.; Akiba, H.; Yamazaki, T.; Azuma, M.; Iwai, H.; Khoury, S.J., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 2003, 198, 63–69
41. Hatachi, S.; Iwai, Y.; Kawano, S.; Morinobu, S.; Kobayashi, M.; Koshiba, M.; Yamazaki, T.; Azuma, M.; Iwai, H.; Khoury, S.J. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol.2003, 30, 1410–1419
42. Kobayashi, M.; Kawano, S.; Hatachi, S.; Kurimoto, C.; Okazaki, T.; Iwai, Y.; Yamazaki, T.; Azuma, M.; Iwai, H.; Khoury, S.J., et al. Enhanced expression of programmed death-1 (PD-1)/ PD-L1 in salivary glands of patients with Sjögren’s syndrome. J. Rheumatol. 2005, 32, 2156–2163
43. Bertias, G.K.; Nakou, M.; Choulaki, C.; Raptopoulos, A.; Papadimitraki, E.; Goulielmos, G.; Kritikos, H.; Sidiropoulos, P.; Tzardi, M.; Kardassis, D., et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in systemic lupus erythematosus. Arthritis Rheum. 2009, 60, 207–218
44. Lili, Y.; Yi, W.; Ji, Y.; Yue, S.; Weimin, S.; Ming, L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS ONE 2012, 7, e37513
45. Tembhre, M.K.; Parihar, A.S.; Sharma, V.K.; Sharma, A.; Chattopadhyay, P.; Gupta, S. Alteration in regulatory T cells and programmed death (PD)1 expressing regulatory T cells in active generalized vitiligo and their clinical correlation. Br. J. Dermatol. 2015, 172, 940–950
46. Tsutsumi, Y.; Jie, X.; Ihara, K.; Nomura, A.; Kanemitsu, S.; Takada, H.; Hara, T. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet. Med.2006, 23, 1145–1150
47. Fujisawa, R.; Haseda, F.; Tsutsumi, C.; Hiromine, Y.; Noso, S.; Kawabata, Y.; Mitsui, S.; Terasaki, J.; Ikegami, H.; Imagawa, A., et al. Low PD-1 expression in peripheral CD4+ T-cells in Japanese patients with autoimmune type 1 diabetes. Clin. Exp. Immunol. 2015, 180, 452–457
48. Nielsen, C.; Hansen, D.; Husby, S.; Jacobsen, B.B.; Lillevang, S.T. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003, 62, 492–497
49. Ni, R.; Ihara, K.; Miyako, K.; Kuromaru, R.; Inuo, M.; Kohno, H.; Matsuura, N.; Yoshimura, A.; Hara, T. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum. Genet. 2007, 121, 223–232
50. Putnam, A.L.; Brusko, T.M.; Lee, M.R.; Liu, W.; Szot, G.L.; Ghosh, T.; Atkinson, M.A.; Bluestone, J.A. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009, 58, 652–662
51. Wong, M.; La Cava, A.; Hahn, B.H. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J. Immunol. 2013, 190, 5402–5410
52. Raimondi, G.; Shufesky, W.J.; Tokita, D.; Morelli, A.E.; Thomson, A.W. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 2006, 176, 2808–2816
53. Franceschini, D.; Paroli, M.; Francavilla, V.; Videtta, M.; Morrone, S.; Labbadia, G.; Atkinson, M.A.; Bluestone, J.A. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Investig. 2009, 119, 551–564
54. Gotot, J.; Gottschalk, C.; Leopold, S.; Knolle, P.A.; Yagita, H.; Kurts, C.; Ludwig-Portugall, I. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc. Natl. Acad. Sci. USA 2012, 109, 10468–10473
55. Wang, J.; Yoshida, T.; Nakaki, F.; Hiai, H.; Okazaki, T.; Honjo, T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 2005, 102, 11823–11828
56. Pauken, K.E.; Jenkins, M.K.; Azuma, M.; Fife, B.T. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes 2013, 62, 2859–2869
57. Nervi, S.; Atlan-Gepner, C.; Fossat, C.; Vialettes, B. Constitutive impaired TCR/CD3-mediated activation of T cells in IDDM patients co-exist with normal co-stimulation pathways. J. Autoimmun. 1999, 13, 247–255
58. Tree, T.I.M.; Roep, B.O.; Peakman, M. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: Report of the Immunology of Diabetes Society T Cell Workshop. Ann. N. Y. Acad. Sci. 2006, 1079, 9–18
59. Long, S.A.; Cerosaletti, K.; Bollyky, P.L.; Tatum, M.; Shilling, H.; Zhang, S.; Zhang, Z.Y.; Pihoker, C.; Sanda, S.; Greenbaum, C., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59, 407–415
60. Michalek, J.; Vrabelova, Z.; Hrotekova, Z.; Kyr, M.; Pejchlova, M.; Kolouskova, S.; Faresjö, M.; Stechova, K. Immune regulatory T cells in siblings of children suffering from type 1 diabetes mellitus. Scand. J. Immunol. 2006, 64, 531–535
61. Xufré, C.; Costa, M.; Roura-Mir, C.; Codina-Busqueta, E.; Usero, L.; Pizarro, E.; Faresjö, M.; Stechova, K. Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients. Int. Immunol.2013, 25, 563–574
62. Jin, Y.; Chen, X.; Podolsky, R.; Hopkins, D.; Makala, L.H.C.; Muir, A.; She, J.X. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin. Immunol.2009, 130, 272–279
63. Kriegel, M.A.; Lohmann, T.; Gabler, C.; Blank, N.; Kalden, J.R.; Lorenz, H.-M. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 2004, 199, 1285–1291
64. Gianchecchi, E.; Crinò, A.; Giorda, E.; Luciano, R.; Perri, V.; Lo Russo, A.; Cappa, M.; Rosado, M.M.; Fierabracci, A. Altered B cell homeostasis and Toll-like receptor 9-driven response in Type 1 diabetes carriers of the C1858T PTPN22 allelic variant: Implications in the disease pathogenesis. PLoS ONE 2014, 9, e110755
65. Del Fattore, A.; Luciano, R.; Pascucci, L.; Goffredo, B.M.; Giorda, E.; Scapaticci, M.; Fierabracci, A.; Muraca, M. Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on t lymphocytes. Cell Transplant.2015, doi:10.3727/096368915X687543
66. Carter, L.; Fouser, L.A.; Jussif, J.; Fitz, L.; Deng, B.; Wood, C.R.; Collins, M.; Honjo, T.; Freeman, G.J.; Carreno, B.M. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur. J. Immunol.2002, 32, 634–643
67. Baraut, J.; Grigore, E.I.; Jean-Louis, F.; Khelifa, S.H.; Durand, C.; Verrecchia, F.; Farge, D.; Michel, L. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: A pilot study. Bone Marrow Transplant. 2014, 49, 349–354.